Similar articles for PMID: 12662148

Year	Number of Results
1945	1
1998	1
1999	1
2000	1
2002	3
2003	8
2004	15
2005	15
2006	20
2007	19
2008	19
2009	10
2010	3
2011	3
2012	3
2013	1
2018	1
2020	1
2021	1
2024	0

1

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.

Cather JC, Cather JC, Menter A. Cather JC, et al. Expert Opin Biol Ther. 2003 Apr;3(2):361-70. doi: 10.1517/14712598.3.2.361. Expert Opin Biol Ther. 2003. PMID: 12662148 Review.

2

[The lymphocyte: protagonism in the new era of the biological therapies].

Gutiérrez M, Ruiz Carrascosa JC. Gutiérrez M, et al. Actas Dermosifiliogr. 2008 Jan;99 Suppl 1:2-8. doi: 10.1016/s0001-7310(08)76193-3. Actas Dermosifiliogr. 2008. PMID: 18341848 Free article. Review. Spanish.

3

[Efalizumab].

Descamps V. Descamps V. Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. doi: 10.1016/s0151-9638(06)70989-9. Ann Dermatol Venereol. 2006. PMID: 17053736 Review. French.

4

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.

Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, Garovoy M, Kwon P, Walicke P, Dedrick R. Joshi A, et al. J Clin Pharmacol. 2006 Jan;46(1):10-20. doi: 10.1177/0091270005283282. J Clin Pharmacol. 2006. PMID: 16397279 Review.

5

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P. Jullien D, et al. Dermatology. 2004;208(4):297-306. doi: 10.1159/000077660. Dermatology. 2004. PMID: 15178911 Review.

6

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.

Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D; Efalizumab Study Group. Lebwohl M, et al. N Engl J Med. 2003 Nov 20;349(21):2004-13. doi: 10.1056/NEJMoa030002. N Engl J Med. 2003. PMID: 14627785 Free article. Clinical Trial.

7

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Gottlieb AB, et al. Arch Dermatol. 2002 May;138(5):591-600. doi: 10.1001/archderm.138.5.591. Arch Dermatol. 2002. PMID: 12020219 Clinical Trial.

8

Efalizumab: a biological agent for the treatment of psoriasis.

Hodulik S, Hadi S. Hodulik S, et al. Rev Recent Clin Trials. 2006 May;1(2):165-8. doi: 10.2174/157488706776876436. Rev Recent Clin Trials. 2006. PMID: 18473968 Review.

9

Efalizumab for the treatment of moderate to severe plaque psoriasis.

Jordan JK. Jordan JK. Ann Pharmacother. 2005 Sep;39(9):1476-82. doi: 10.1345/aph.1G074. Epub 2005 Jul 5. Ann Pharmacother. 2005. PMID: 15998666 Review.

10

The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.

Bonnekoh B, Böckelmann R, Pommer AJ, Malykh Y, Philipsen L, Gollnick H. Bonnekoh B, et al. Skin Pharmacol Physiol. 2007;20(2):96-111. doi: 10.1159/000097982. Epub 2006 Dec 13. Skin Pharmacol Physiol. 2007. PMID: 17167274

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

121 results

Results by year